Comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA at the 1:3 conversion ratio for the treatment of asymmetry after long-term facial paralysis

Plastic and Reconstructive Surgery

Volumn 135, Issue 1, 2015, Pages 239-249

  Remigio, Adelina Fatima Do Nascimento ^a   Salles, Alessandra Grassi ^a   De Faria, José Carlos Marques ^a   Ferreira, Marcus Castro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ADULT; AGED; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DRUG THERAPY; ETIOLOGY; FACE ASYMMETRY; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; FACIAL ASYMMETRY; FACIAL PARALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925284054     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0000000000000800     Document Type: Article

References (46)

1. Ferreira MC. Aesthetic considerations in facial reanimation. Clin Plast Surg. 2002;29:523-532.
2. Salles AG, Toledo PN, Ferreira MC. Botulinum toxin injection in long-standing facial paralysis patients: Improvement of facial symmetry observed up to 6 months. Aesthetic Plast Surg. 2009;33:582-590.
3. Clark RP, Berris CE. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 1989;84:353-355.
4. Clark RP, Berris CE. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 2005;115:573-574.
5. Sadiq SA, Khwaja S, Saeed SR. Botulinum toxin to improve lower facial symmetry in facial nerve palsy. Eye (Lond.) 2012;26:1431-1436.
6. Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol. 2013;34:319-324.
7. Mehta RP, Hadlock TA. Botulinum toxin and quality of life in patients with facial paralysis. Arch Facial Plast Surg. 2008;10:84-87.
8. Salles AG, Ferreira MC. Botulinum toxin in the treatment of the synkinesis associated with facial paralysis: Preliminary report. Plast Reconstr Surg. 2012;130:49-50.
9. Cecini M, Pavese C, Comelli M, et al. Quantitative measurement of evolution of postparetic ocular synkinesis treated with botulinum toxin type A. Plast Reconstr Surg. 2013;132:1255-1264.
10. Salles AG. Discussion: Quantitative measurement of evolution of postparetic ocular synkinesis treated with botulinum toxin type A. Plast Reconstr Surg. 2013;132:1265-1267.
11. Choi KH, Rho SH, Lee JM, Jeon JH, Park SY, Kim J. Botulinum toxin injection of both sides of the face to treat post-paralytic facial synkinesis. J Plast Reconstr Aesthet Surg. 2013;66:1058-1063.
12. Guntinas-Lichius O, Glowka TR, Angelov DN, Irintchev A, Neiss WF. Improved functional recovery after facial nerve reconstruction by temporary denervation of the contralateral mimic musculature with botulinum toxin in rats. Neurorehabil Neural Repair 2011;25:15-23.
13. Borodic GE, Cheney M, McKenna M. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg. 1992;90:972-977.
14. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186-1194.
15. Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist 2008;14:289-298.
16. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004;19(Suppl 8):S129-S136.
17. Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235: 197-199.
18. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
19. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39:1815-1820.
20. Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin. 2005;45:25-37.
21. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and Botox in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov Disord. 2005;20:937-944.
22. Cliff SH. Migration characteristics of botulinum neurotoxins. Cosmet Dermatol. 2007;7:32-35.
23. Lowe NJ. Overview of botulinum neurotoxins. J Cosmet Laser Ther. 2007;9(Suppl 1):11-16.
24. Ipsen Biopharm. Dysport: Toxina botulínica tipo A. Product information for the health professional. Berkshine, United Kingdom: Ipsen Biopharm Ltd. Available at: http://www.galderma. com.br/-inc/downloads-medicamentos/Dysport. pdf. Accessed December 26, 2013.
25. Carruthers A, Carruthers J, Lowe NJ, Menter A, Gibson J. Oneyear, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res. 2004;7:1-20.
26. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized study. J Am Acad Dermatol. 2006;55:975-980.
27. Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33:S37-S43.
28. Stotland MA, Kowalski JW, Ray BB. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: Results from a prospective open-label study. Plast Reconstr Surg. 2007;120:1386-1394.
29. Roche N, Schnitzler A, Genêt F F, Durand MC, Bensmail D. Undesirable distant effects following botulinum toxin type a injection. Clin Neuropharmacol. 2008;31:272-280.
30. Navarrete Alvaro ML, Junyent J, Torrent L. Botulinum toxin and facial palsy: Our experience (in Spanish). Acta Otorrinolaringol Esp. 2010;61:277-281.
31. Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: Long-term treatment with either Botox or Dysport. J Neural Transm. 2010;117:759-763.
32. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: An evidence-based review. Plast Reconstr Surg. 2008;121:413e-422e.
33. Hexsel D, Brum C, do Prado DZ, et al. Field effect of two commercial preparations of botulinum toxin type A: A prospective, double-blind, randomized clinical trial. J Am Acad Dermatol. 2012;67:226-232.
34. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59:102-103.
35. Talarico Filho S, Nascimento MM, Macedo FS, Pecora CS. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg. 2007;33:S44-S50.
36. Nettar KD, Yu KC, Bapna S, Boscardin J, Mass CS. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg. 2011;13:380-386.
37. Karsai S, Adrian R, Hammes S, Thimm J, Raulin C. A randomized double-blind study of the effect of Botox and Dysport/ Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol. 2007;143:1447-1449.
38. VanSwearingen JM, Brach JS. The Facial Disability Index: Reliability and validity of a disability assessment instrument for disorders of the facial neuromuscular system. Phys Ther. 1996;76:1288-1300.
39. Ho AL, Scott AM, Klassen AF, Cano SJ, Pusic AL, Van Laeken N. Measuring quality of life and patient satisfaction in facial paralysis patients: A systematic review of patient-reported outcome measures. Plast Reconstr Surg. 2012;130:91-99.
40. Ferreira MC, Marques de Faria JC. Result of microvascular gracilis transplantation for facial paralysis-personal series. Clin Plast Surg. 2002;29:515-522.
41. Saldanha OR, Salles AG, Ferreira MC, et al. Aesthetic evaluation of lipoabdominoplasty in overweight patients. Plast Reconstr Surg. 2013;132:1103-1112.
42. Kassir R, Kolluru A, Kassir M. Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial rhytids. Dermatol Ther (Heidelb.) 2013;3:179-189.
43. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35:1-8.
44. Manstein CH, Beidas OE. Comparing clinical efficacy of botox and dysport in a small group of patients. Plast Reconstr Surg. 2011;128:26e-27e.
45. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994;344:474-475.
46. Ferreira MC, Salles AG, Gimenez R, Soares MF. Complications with the use of botulinum toxin type a in facial rejuvenation: Report of 8 cases. Aesthetic Plast Surg. 2004;28:441-444.